1. Generics Bulletin
  2. >>Business
  3. >>Deals

Accord Aims At Addiction With Buprenorphine Implant Deal

Agreement Sees Firm Distribute Sixmo For Molteni Farmaceutici In Europe

 
• By Dave Wallace

Accord is kicking off plans to launch a number of addiction treatments by partnering with Molteni Farmaceutici on distributing its Sixmo six-month buprenorphine implant in Europe.

Calendar
Sixmo is a six-month buprenorphine implant • Source: Shutterstock

Accord Healthcare says it is kicking off plans to launch a number of addiction treatments by striking an exclusive partnership deal with Molteni Farmaceutici to distribute its Sixmo six-month buprenorphine implant in Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.